Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cDTPA-PAI2
- Development stage
- Unknown
- Lead developer
- Biotech Australia
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intraperitoneal
01
Overview
cDTPA-PAI2 is a chelator-protein conjugate consisting of the cyclic anhydride of diethylenetriaminepentacetic acid (cDTPA) covalently bound to plasminogen activator inhibitor type 2 (PAI2). This compound serves as the unlabeled precursor for the targeted alpha therapy agent 213Bi-PAI2. The PAI2 component specifically targets the urokinase plasminogen activator (uPA) and its receptor (uPAR) complex, which is overexpressed on the surface of various malignant cells. Once labeled with the alpha-emitter Bismuth-213, the resulting radiopharmaceutical delivers high-energy radiation directly to the tumor site, inducing apoptosis and inhibiting tumor growth. Preclinical studies have investigated its efficacy in prostate, breast, ovarian, and pancreatic cancers, particularly for treating micrometastases and minimal residual disease. The protein component was originally provided by Biotech Australia.
- Other names
- cyclic DTPA-PAI2cDTPA-plasminogen activator inhibitor type 2
02
Targets
LSR (Lipolysis-stimulated lipoprotein receptor)PLAU (uPA)
Beyond the preview
Go deeper on cDTPA-PAI2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cDTPA-PAI2.